PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Akoya Biosciences, Inc. (AKYA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00974H1041
CUSIP00974H104
SectorHealthcare
IndustryMedical Instruments & Supplies

Highlights

Market Cap$235.38M
EPS-$1.43
PE Ratio30.63
PEG Ratio0.75
Revenue (TTM)$96.63M
Gross Profit (TTM)$43.39M
EBITDA (TTM)-$47.14M
Year Range$3.04 - $8.80
Target Price$8.64
Short %2.66%
Short Ratio4.29

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AKYA

Akoya Biosciences, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akoya Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%OctoberNovemberDecember2024FebruaryMarch
-81.84%
25.40%
AKYA (Akoya Biosciences, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Akoya Biosciences, Inc. had a return of -3.07% year-to-date (YTD) and -41.75% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-3.07%10.04%
1 month-12.73%3.53%
6 months0.00%22.79%
1 year-41.75%32.16%
5 years (annualized)N/A13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20244.10%12.99%
2023-24.64%-10.58%-24.73%25.43%11.16%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Akoya Biosciences, Inc. (AKYA) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AKYA
Akoya Biosciences, Inc.
-0.55
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Akoya Biosciences, Inc. Sharpe ratio is -0.55. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.55
2.76
AKYA (Akoya Biosciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Akoya Biosciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-81.84%
0
AKYA (Akoya Biosciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akoya Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akoya Biosciences, Inc. was 87.98%, occurring on Oct 27, 2023. The portfolio has not yet recovered.

The current Akoya Biosciences, Inc. drawdown is 81.84%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.98%Apr 19, 2021638Oct 27, 2023

Volatility

Volatility Chart

The current Akoya Biosciences, Inc. volatility is 20.48%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%OctoberNovemberDecember2024FebruaryMarch
20.48%
2.82%
AKYA (Akoya Biosciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akoya Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items